Clinical Trial Update: Trifluridine/tipiracil (TAS-102), Bevacizumab, and Camrelizumab As Third-line or Later-line Therapy of Gastric Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating a triplet therapy of trifluridine/tipiracil (TAS-102), bevacizumab, and camrelizumab for third-line or later treatment of m…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Camrelizumab (camrelizumab)
• Lonsurf (trifluridine/tipiracil)

Snippet

Sponsor: LIN YANG | Conditions: Gastric Cancer Adenocarcinoma Metastatic | Phase 2 | Status: RECRUITING